Ocular Therapeutix
OCUL
127 hedge funds and large institutions have $214M invested in Ocular Therapeutix in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 16 closing their positions.
107% more call options, than puts
Call options by funds: $4.01M | Put options by funds: $1.94M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
93% more capital invested
Capital invested by funds: $111M → $214M (+$103M)
69% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 16
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
9% more funds holding
Funds holding: 116 → 127 (+11)
0.8% more ownership
Funds ownership: 51.45% → 52.24% (+0.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.55M |
| 2 |
Morgan Stanley
New York
|
+$3.58M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$2.35M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.73M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$4.37M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.62M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$1.91M |
| 5 |
Renaissance Technologies
New York
|
-$1.06M |
OCUL Hedge Fund Activity: Q1 2023 in Review
127 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2023, worth a combined $214M — up 93% from $111M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new OCUL positions and 16 closed out — a net gain of 11 holders — while 39 added to existing stakes and 33 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.55M. The largest seller was Emerald Advisers, cutting an estimated $4.37M.
- 127 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2023, up from 116 in Q4 2022.
- Funds reported $214M of Ocular Therapeutix stock for Q1 2023, up 93% quarter-over-quarter.
- 27 funds opened new Ocular Therapeutix positions in Q1 2023 and 16 closed out, a net change of +11 holders.
- The largest Ocular Therapeutix buyer in Q1 2023 was Millennium Management, an estimated $4.55M added.
- The largest Ocular Therapeutix seller in Q1 2023 was Emerald Advisers, an estimated $4.37M sold.
Based on aggregated 13F filings for Q1 2023.